Skip to main content
Medical information Clinical review pending

Cytogenetics

FISH MDM2 12q15 Gene Amplification Test

The FISH MDM2 12q15 Gene Amplification Test uses Fluorescence In Situ Hybridization (FISH) to detect amplification of the MDM2 gene on chromosome 12q15, which is associated with certain cancers. This test aids oncologists in diagnosis and treatment planning.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Formalin-fixed paraffin-embedded (FFPE) tissue block containing at least 10% tumor tissue.
Results
Confirm with the laboratory before booking.
Preparation
No patient preparation is required. Ensure the tissue block is properly labeled and accompanied by a completed Chromosome & FISH Analysis Requisition Form (Form 17).
Test priceKSh 21,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the FISH MDM2 12q15 Gene Amplification Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of certain cancers, particularly soft tissue sarcomas.
  • ✓Prognosis assessment in specific cancer types.
  • ✓Guiding treatment decisions for cancers associated with MDM2 amplification.
  • ✓Patients with suspected cancer based on clinical presentation.
  • ✓Patients with a family history of relevant cancers.
02

In plain language

What this test helps you understand

This test helps identify MDM2 gene amplification, a genetic alteration associated with certain cancers. This information can assist oncologists in diagnosis, prognosis, and guiding treatment decisions.
The FISH MDM2 12q15 Gene Amplification Test is a diagnostic tool used in oncology to detect specific genetic changes linked to cancer. It uses Fluorescence In Situ Hybridization (FISH) technology to examine the MDM2 gene located on chromosome 12q15. Identifying amplification of this gene can provide valuable information for cancer diagnosis and treatment decisions.

This test specifically looks for an increase in the number of copies of the MDM2 gene (amplification). This genetic alteration is found in some types of cancer, including certain soft tissue sarcomas and breast cancers. Understanding if this amplification is present can help healthcare providers assess the potential aggressiveness of a tumor and guide treatment strategies.

Patients experiencing cancer symptoms, those with a family history of cancer, or individuals identified as high-risk by their doctor may be recommended for this test. Discuss with your physician if this test is appropriate for your situation.

Benefits of this test include aiding in the early detection of specific genetic alterations associated with cancer, supporting informed decisions about treatment options, and potentially contributing to personalized treatment plans. Results help oncologists understand the tumor's characteristics and monitor treatment response.

Results will indicate whether MDM2 gene amplification is detected. Discuss the results thoroughly with your oncologist to understand their implications for your specific condition and next steps.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo patient preparation is required. Ensure the tissue block is properly labeled and accompanied by a completed Chromosome & FISH Analysis Requisition Form (Form 17).
SampleFormalin-fixed paraffin-embedded (FFPE) tissue block containing at least 10% tumor tissue.
MethodologyFluorescence In Situ Hybridization (FISH)
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects MDM2 gene amplification but does not identify all possible genetic alterations associated with cancer. Results must be interpreted by a qualified healthcare professional in conjunction with other clinical and pathological findings. The test requires adequate tumor tissue in the sample.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

MDM2 is a gene located on chromosome 12. Amplification, or an increase in the number of copies of this gene, is associated with certain types of cancer.
FISH stands for Fluorescence In Situ Hybridization. It is a laboratory technique used to detect and locate specific DNA sequences on chromosomes.
Your doctor may recommend this test if you have symptoms suggestive of cancer, a family history of cancer, or if they suspect a specific type of cancer associated with MDM2 amplification.
The test requires a formalin-fixed paraffin-embedded tissue block, typically obtained from a biopsy or surgery.
Turnaround time varies. Please confirm the current estimated turnaround time with the laboratory before booking.
Results will indicate if MDM2 gene amplification was detected. Your doctor will interpret these results in the context of your overall health and discuss the implications with you.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp